AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read$PDSB

PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

Original reporting
tradingview.com
Published Oct 21, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts — source image
Source · tradingview.com
Decision brief

The 30-second read

$PDSBBullishMed
01

Why it matters

The disclosed efficacy and survival metrics are likely to generate short‑term buying interest and may influence valuation models for the company.

02

Market read

New Phase 2 data provide fresh material for traders; the news is timely and could affect PDSB's stock price in the near term.

03

What to watch

Potential regulatory hurdles, competition from other mCRC treatments, and the need for financing to complete Phase 3.

Relevance 8/10Novelty 8/10Timing: immediate, as the data were just released in the filing

Background

The filing updates PDS Biotechnology's corporate presentation with recent trial outcomes and upcoming data milestones.

Company-level read

Ticker impact

$PDSBBullishHigh confidence
Context

PDS Biotechnology disclosed Phase 2 interim results for PDS0301 showing a 71.4% objective response rate and ~80% 24‑month survival, plus upcoming data readouts through 2028.

Expected impact

likely upward pressure as the market prices in the strong efficacy signals.

Evidence & confidence

Phase 2 data with high response and survival rates are material for a biotech and often trigger buying interest ahead of further readouts.

Market effects

Sector

Strengthens the oncology pipeline narrative, may lift peer biotech stocks developing similar mCRC therapies.

Regional

Primarily U.S. biotech investors; limited broader market effect.

Global

Limited to biotech sector, no macro impact.

Counterpoint

What could challenge this read

Skeptics may argue that interim data are not definitive and that later Phase 3 outcomes could differ.

Key entities

  • company
    PDS Biotechnology Corp

    Biotech firm developing PDS0301 and PDS0101 oncology therapeutics.

  • person
    Dr. Patrick Soon‑Shiong

    New board member following September financing.

Read at source← All news

Related articles

OCT 16
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com2 min
OCT 13
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com6 min
SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min